NaxSwab™ OTC novel naloxone nasal swab demonstrates faster absorption and higher early exposures against other naloxone products in clinical study

Pharmacokinetic study data in healthy volunteers shows NaxSwab™ OTC has 74% and 1096% higher exposures at 2.5 minutes compared to naloxone HCI 4mg nasal spray and 0.4mg IM naloxone injection BETHESDA, Md., Dec. 1, 2022 /PRNewswire/ — Pocket Naloxone Corp., a startup pharmaceutical…

Click here to view original post